Navigation Links
Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
Date:4/1/2008

Leader in Molecular Cancer Diagnostics Strengthens U.S. Management Along

With U.S. Presence

AMSTERDAM, The Netherlands, April 1, 2008 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, today announced the appointment of Richard A. Bender, MD, FACP to the position of vice president and chief medical officer (CMO). Dr. Bender, who will report directly to Chief Executive Officer (CEO) Dr. Bernhard Sixt, will be responsible for directing all medical activities within Agendia, playing an integral role in defining the strategic vision of the company as it expands its U.S. presence with an Agendia Inc. office in California in the coming months.

"We are very pleased to add a Board certified Oncologist of Dr. Bender's caliber to our management team," said Dr. Sixt. "As we continue to expand our U.S. presence and the use of our MammaPrint(R) diagnostic service by U.S.- based patients, we are confident that Dr. Bender's wealth of experience will play a critical role in the company's strategic planning and execution of our clinical programs."

"We are delighted to welcome Dr. Bender to the Agendia team," said Dr. Jan Groen, chief operating officer (COO) of Agendia. "His reputation and broad experience in the field of oncology, including treatment, drug development and genomic assays, will be an extremely valuable asset to our company as we increase our global presence."

"I am very excited to be joining Agendia at such a pivotal and exciting time in the company's development," said Dr. Bender. "Their FDA cleared breast cancer prognostic test MammaPrint clearly shows that Agendia is becoming an important diagnostic provider for the management of breast cancer. The company's promising oncology pipeline and its depth of expertise shows that the company is positioned very well to achieve its goal of bringing innovative cancer diagnostics to patient care."

Most
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
2. Time Magazine Names Agendia Test a Best Invention of 2007
3. Investigational anti-restenosis drug pimecrolimus disappoints
4. Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director
5. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
6. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
7. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
8. Management Consulting Group PLC Appoints Kurt Salmon Associates Chairman Mark Wietecha to its Board of Directors
9. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
10. AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer
11. Digirad Corporation Appoints John W. Sayward to Its Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)... Traditional healthcare,s uncertain future and ...lternative care. Affordable Acupuncture Scottsdale...EB) November 29, 2009 -- Affordable Acupuncture, L...) and has been met with enthusiasm and gratitude. ... attributed to two things, need and cost. "A...
(Date:11/28/2009)...help lift spirits, recognize signs of depression ,... For many seniors, the holiday season can trigger ...ruggle with health issues or worry about money pro...y. , To help overcome the seasonal blues, the A...wing advice: , Get out and socialize or invite f...
(Date:11/27/2009)...CO, Nov. 27 The Gymboree... Lambert, CFO/COO, will present at the NASDAQ OMX ...ay Fair Hotel in London, England, on Wednesday, De... to a live broadcast of The Gymboree Corporation,s...www.gymboree.com, click on "Our Company" at the bo...
(Date:11/27/2009)...us low-emission vehicles may reduce future disease.... 27 (HealthDay News) -- Encouraging city dwellers...ffer much greater public health benefits than incr...ers have found. , The study compared the projec...nd transport scenarios for London, England, and De...
(Date:11/27/2009)... Specialist manufacturers who use medical load ...llions of dollars by bringing in technology partne...numbers of pro-active medical manufacturers are ca...stage of their projects, ensuring that progress wi... or potentially outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...on , , SATURDAY, Nov. 29 (HealthDay News) ...afe, itch and develop dry patches, but there are a... says Jeff Moore, an instructor of pharmaceutics a... infection," Moore said in a university news relea...
... /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (N...hairman and Chief Executive Officer, Bob Rieder, w... 45,000 common shares from his direct holding of C...uch an inopportune time; however the global financ...
...obal observance of World AIDS Day, a time during w...rage of the 33 million people living with and affe...e to remember those whose lives,have been lost. I...cy Plan for AIDS Relief (PEPFAR/Emergency Plan), t...
...Inc. (Nasdaq: STRM ) announced today it will rel...scal year 2008 ended October 31, 2008 on Monday, D...rence call and webcast to discuss,the results on M...necessary audit work to finalize the results. , ...
...rfect,holiday gift? Maybe it,s time to help your ...thier smile. , , Listen to this report from P...story=36013 , , Registered journalists can a... at http://www.mediaseed.tv . , 11NY08-0055...
...S Day on Monday, December 1, the Global AIDS Allia...n to intensify the US effort against HIV/AIDS, bot..." , , Over 100 global health advocacy organiz...mo is online: , , http://www.globalaidsallia...
Other Medicine News:Health News:Dry Skin? Don't Let Winter Win 2Health News:Cardiome Discloses Chairman And CEO's Involuntary Share Sale 2Health News:Cardiome Discloses Chairman And CEO's Involuntary Share Sale 3Health News:From USAID Administrator, Henrietta H. Fore: Renewed Commitment On World AIDS Day 2Health News:Streamline Health Reschedules Q3 Financial Results Release and Conference Call for Monday, December 15, 2008 2Health News:World AIDS Day December 1st: Obama Needs to Lead 2
(Date:11/29/2009)... FUJIFILM Medical Systems USA, Inc. is pleased to ...l DR cassette, at the 2009 Radiological Society of...ny clinical environment, FDR D-EVO uses an innovat...film,s trademark image quality and outstanding fle...o transition to DR without modification to the exa...
(Date:11/29/2009)... Researchers using functional magnetic resonance i... that men and women respond differently to positiv...nted today at the annual meeting of the Radiologic... direct more attention to sensory aspects of emoti...implications for required action, whereas women di...
(Date:11/27/2009)...swire/ -- ACUO TECHNOLOGIES, developers of high-pe...migration tools and services, is pleased to announ...ice has approved a patent application for an "Asse... Acuo Technologies is pleased to add the U.S. pate...eneral, the granted patent application broadly pro...
Breaking Medicine Technology:FUJIFILM's DR Cassette Makes World Debut 2New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Treating ROP in tiny preemies 3B better glaucoma follow up in urban clinic 60035 1Treating ROP in tiny preemies 3B better glaucoma follow up in urban clinic 60035 2Treating ROP in tiny preemies 3B better glaucoma follow up in urban clinic 60035 3Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 1Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 2Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 3Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 4Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 5Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 6Orexigen 28R 29 Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk 60031 7Gene Therapy Offers Hope for Severe Hereditary Eye Disease 60029 1Gene Therapy Offers Hope for Severe Hereditary Eye Disease 60029 2
...AN FRANCISCO, June 9 Halozyme Therapeutics,Inc. (...oping and,commercializing products targeting the e...ata for the company,s diabetes mellitus program at...ic Sessions. The data,showed that combining the co...e enzyme (rHuPH20) with Humulin R(R) (regular insu...
...SPIRE IRB Is Exhibiting at Bio International Conve... 17-20, Currently, over 54,255 Trials with L... Place, SAN DIEGO, June 9 ASPI...nt Review Board (IRB), is,responsible for overseei...of people participating in clinical trials. ASPIRE...
Other Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5ASPIRE Independent Review Board Announces 10 Ways to Protect Participants' Rights in Clinical Drug Trials and Optimize Results From Research 2ASPIRE Independent Review Board Announces 10 Ways to Protect Participants' Rights in Clinical Drug Trials and Optimize Results From Research 3
Penicillin-Streptomycin Mixture
PEN-STREP, 100X
Gentamicin, 10 mg/ml
GENTAMICIN SULFATE, 1000X
Medicine Products: